Department of Otorhinolaryngology, Head and Neck Surgery, Universitätsklinikum Erlangen, Friedrich-Alexander University of Erlangen-Nürnberg (FAU), Erlangen, Germany.
Eur Rev Med Pharmacol Sci. 2018 May;22(10):2949-2953. doi: 10.26355/eurrev_201805_15049.
After that the establishment of transoral robotic surgery (TORS) for head and neck cancer has been adopted in North America, it has also recently been adopted in Europe. In these parts, transoral laser microsurgery (TLM) is widely applied. The aim of the study was to identify the absolute number of operations amenable to TORS at a TORS initiating institution on the basis of all former TLM cases.
All laser surgery procedures from May 2004 to April 2013 (108 months) were initially retrospectively registered; after that, all stage pT1 and pT2 squamous cell carcinomas of the oropharynx, hypopharynx, and larynx were selected.
Over a period of nine years out of all TLM cases, there were 45 cases of pT1 and pT2 orohypopharyngeal and supraglottic squamous cell carcinomas, which could have been considered for TORS surgery. With the inclusion of a nowadays-typical TORS indication such as tonsil cancer, 142 cases would have been amendable to TORS.
The indication for TORS would have been made in five of the TLM cases per year. Institutions initiating TORS, which own an intensive TLM experience, are encouraged to TORS indications in more than solely typical TLM indications. By indicating TORS instead of handheld surgery, a higher caseload of more than 15 cases per year can be achieved for TORS indications.
经口机器人手术(TORS)在北美成功应用于头颈部肿瘤治疗后,最近也在欧洲得到应用。在这些地区,经口激光微创手术(TLM)被广泛应用。本研究旨在根据所有以前的 TLM 病例,确定 TORS 启动机构可进行 TORS 的绝对手术数量。
最初回顾性登记了 2004 年 5 月至 2013 年 4 月(108 个月)所有激光手术病例;之后,选择所有分期 pT1 和 pT2 口咽、下咽和喉鳞状细胞癌病例。
在 9 年的 TLM 病例中,有 45 例 pT1 和 pT2 口咽和下咽及喉鳞状细胞癌病例可考虑行 TORS 手术。如果包括目前 TORS 的典型适应证如扁桃体癌,有 142 例病例可采用 TORS。
TLM 每年可进行 5 例 TORS 手术。建议具有丰富 TLM 经验的 TORS 启动机构不仅在 TLM 典型适应证方面,而且在更多适应证方面开展 TORS 手术。通过指示 TORS 而不是手持手术,可使 TORS 适应证的病例数每年增加 15 例以上。